BetaSite sustained release formulation of the beta blocker levobunolol data

The Alameda, Calif., company announced positive Phase III results, testing doses of 0.1 percent or 0.5 percent BetaSite against 0.5 percent levobunolol in 670 patients.

Patients instilled the eyedrops twice daily for three months. Patients using 0.1 percent BetaSite had a mean reduction in intraocular pressure (IOP) of 21 percent. A 20 percent reduction is considered clinically relevant. Patients using 0.5 percent BetaSite had a 25 percent reduction in IOP, the same as patients using conventional levobunolol. ...